Yanyan Lou

8.4k total citations · 4 hit papers
122 papers, 5.3k citations indexed

About

Yanyan Lou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Yanyan Lou has authored 122 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 32 papers in Immunology. Recurrent topics in Yanyan Lou's work include Cancer Immunotherapy and Biomarkers (49 papers), Lung Cancer Treatments and Mutations (40 papers) and Lung Cancer Research Studies (26 papers). Yanyan Lou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (49 papers), Lung Cancer Treatments and Mutations (40 papers) and Lung Cancer Research Studies (26 papers). Yanyan Lou collaborates with scholars based in United States, China and Australia. Yanyan Lou's co-authors include Julian A. Marin‐Acevedo, Bhagirathbhai Dholaria, Patrick Hwu, Keith L. Knutson, Aixa Soyano, Rami Manochakian, Chengwen Liu, Saranya Chumsri, Willem W. Overwijk and Gregory Lizée and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Yanyan Lou

111 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Next generation of immune checkpoint therapy in cancer: new developments and challenges

2018 608 citations Julian A. Marin‐Acevedo, Keith L. Knutson et al. Journal of Hematology & Oncology profile →
Next generation of immune checkpoint inhibitors and beyond

2021 402 citations Julian A. Marin‐Acevedo, Yanyan Lou et al. Journal of Hematology & Oncology profile →
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

2016 349 citations Yanyan Lou, Lixia Diao et al. Clinical Cancer Research profile →
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

2021 177 citations Umair Majeed, Rami Manochakian et al. Journal of Hematology & Oncology profile →

Peers

Countries citing papers authored by Yanyan Lou

Since Specialization

Citations

This map shows the geographic impact of Yanyan Lou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanyan Lou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanyan Lou more than expected).

Fields of papers citing papers by Yanyan Lou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanyan Lou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanyan Lou. The network helps show where Yanyan Lou may publish in the future.

Co-authorship network of co-authors of Yanyan Lou

This figure shows the co-authorship network connecting the top 25 collaborators of Yanyan Lou. A scholar is included among the top collaborators of Yanyan Lou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanyan Lou. Yanyan Lou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 2024 ·Cancers ·(unknown), Julian A. Marin‐Acevedo, Leylah Drusbosky, (unknown), Yujie Zhao, Rami Manochakian, Yanyan Lou	3
2	Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1 2024 ·SHILAP Revista de lepidopterología ·Yan Luo, Martha E. Gadd, Yaqing Qie, (unknown), (unknown), Mieu Brooks, (unknown), (unknown), Shuhua Li, (unknown), Yanyan Lou, Tushar Patel, Roxana Dronca, Mohamed A. Kharfan‐Dabaja, Haidong Dong, Alfredo Quiñones‐Hinojosa, Hong Qin	4
3	Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review 2024 ·JCO Precision Oncology ·Jia Luo, Narjust Florez, (unknown), Yanyan Lou, (unknown), C. Patrick, Alexander I. Spira, (unknown), Hatim Husain	3
4	Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02. 2024 ·Journal of Clinical Oncology ·Benjamin Levy, Luis Paz‐Ares, Wu‐Chou Su, (unknown), Tsung‐Ying Yang, Anthony W. Tolcher, Yanyan Lou, Yoshitaka Zenke, Diego Cortinovis, Enriqueta Felip, Manuel Dómine, Konstantinos Leventakos, Emiliano Calvo, Atsushi Horiike, Edward Pan, Daisy Lin, Xiaoyu Jia, (unknown), Michael Chisamore, Yasushi Goto	5
5	Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy 2024 ·Cancers ·(unknown), (unknown), (unknown), Lingzhi Hong, (unknown), (unknown), Shawna M. Hubert, Xiuning Le, Natalie I. Vokes, Kunal Rai, Ara A. Vaporciyan, Don L. Gibbons, John V. Heymach, J. Jack Lee, Scott E. Woodman, Caroline Chung, David A. Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang	1
6	Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer 2023 ·Cancers ·(unknown), (unknown), (unknown), Rami Manochakian, Yujie Zhao, Yanyan Lou	36
7	First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report 2023 ·JTO Clinical and Research Reports ·Umair Majeed, (unknown), Karan Seegobin, Aziza Nassar, Rami Manochakian, Yujie Zhao, Yanyan Lou	3
8	Brief report: risk stratification following curative therapy for stage I NSCLC 2023 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Muhamad Alhaj Moustafa, (unknown), Ruqin Chen, Yujie Zhao, Rami Manochakian, Yanyan Lou	0
9	A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC). 2023 ·Journal of Clinical Oncology ·(unknown), Nathan R. Foster, Yanyan Lou, Yujie Zhao, Mahesh Seetharam, Aaron S. Mansfield, Konstantinos Leventakos, (unknown), (unknown), (unknown), Qian Shi, Sani H. Kizilbash, Haidong Dong, Alex A. Adjei, Wen Wee	2
10	Immune-Related Adverse Events in Patients with Lung Cancer 2023 ·Current Oncology Reports ·(unknown), (unknown), (unknown), (unknown), Yujie Zhao, Yanyan Lou, Rami Manochakian	6
11	A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Rami Manochakian, Yujie Zhao, Manisha Salinas, András Khoór, Jordan D. LeGout, Yanyan Lou	1
12	Protein kinase Cι mediates immunosuppression in lung adenocarcinoma 2022 ·Science Translational Medicine ·Ning Yin, (unknown), Capella Weems, Barath Shreeder, Yanyan Lou, Keith L. Knutson, Nicole R. Murray, Alan P. Fields	11
13	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy 2021 ·JNCI Journal of the National Cancer Institute ·Ying Jing, Yongchang Zhang, Jing Wang, Kunyan Li, Xue Chen, Jianfu Heng, Qian Gao, Youqiong Ye, Zhao Zhang, Yaoming Liu, Yanyan Lou, Steven H. Lin, Lixia Diao, Hong Liu, Xiang Chen, Gordon B. Mills, Leng Han	75
14	Next generation of immune checkpoint inhibitors and beyond breakdown → 2021 ·Journal of Hematology & Oncology ·Julian A. Marin‐Acevedo, (unknown), Yanyan Lou	402
15	Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK ‐positive non‐small‐cell lung cancer: Case report and review of the literature 2021 ·SHILAP Revista de lepidopterología ·(unknown), Katherine S. Tzou, Matthew T. Olson, (unknown), (unknown), David D. Thiel, Yanyan Lou, Yujie Zhao, Rami Manochakian	4
16	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy 2018 ·Cell Systems ·Youqiong Ye, Yu Xiang, (unknown), Yoon-Jin Kim, Chunjie Liu, Peter K. Park, Qingsong Hu, Lixia Diao, Yanyan Lou, Chunru Lin, An‐Yuan Guo, Bingying Zhou, Li Wang, Zheng Chen, Joseph S. Takahashi, Gordon B. Mills, Seung Hee Yoo, Leng Han	197
17	Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma breakdown → 2016 ·Clinical Cancer Research ·Yanyan Lou, Lixia Diao, Edwin R. Parra, Warren L. Denning, Limo Chen, You Hong Fan, Lauren A. Byers, Jing Wang, Vassiliki A. Papadimitrakopoulou, Carmen Behrens, Jaime Canales Rodriguez, Patrick Hwu, Ignacio I. Wistuba, John V. Heymach, Don L. Gibbons	349
18	Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients 2016 ·Value in Health ·Mo Huang, Yanyan Lou, James M. Pellissier, Thomas Burke, (unknown), Ruifeng Xu, (unknown)	3
19	PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines 2012 ·Cancer Research ·Weiyi Peng, Chengwen Liu, Chunyu Xu, Yanyan Lou, Jieqing Chen, Yan Yang, Hideo Yagita∥, Willem W. Overwijk, Gregory Lizée, Laszlo Radvanyi, Patrick Hwu	340
20	Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses 2007 ·The Journal of Immunology ·Yanyan Lou, Chengwen Liu, Grace J. Kim, Yong‐Jun Liu, Patrick Hwu, Gang Wang	112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact